不同的血液蛋白谱与停用英夫利昔单抗的克罗恩病患者短期和中期/长期临床复发风险相关:当缓解状态隐藏不同类型的残留疾病活动时JF - Gut JO - Gut DO - 10.1136/gutjnl-2022-327321 SP - gutjnl-2022-327321 AU - Nicolas Pierre AU - v n Anh Huynh-Thu AU - Thomas Marichal AU - Matthieu Allez AU - Yoram Bouhnik AU - David Laharie AU - Arnaud Bourreille AU - jean - fracimd Colombel AU - Marie-Alice Meuwis AU - Edouard Louis A2 -目的:尽管克罗恩病(CD)患者处于持续稳定的缓解期，但停止抗肿瘤坏死因子α (TNFα)治疗的患者复发率很高(2年内约50%)。需要对这些患者的非侵入性生物学特征进行表征，以更好地指导抗tnf α停药的决定。设计采用接近延伸法测定持续无类固醇缓解和停止抗tnf α(英夫利昔单抗)治疗的CD患者(n=102)血清中的92种免疫相关蛋白。如前所述，基于临床复发时间的分层用于表征复发者的不同生物学特征(短期复发:6个月vs中长期复发:6个月)。通过单变量Cox模型确定蛋白水平与临床复发时间之间的关系。结果中期/长期临床复发风险(HR)与血清中主要表达于淋巴细胞的蛋白(LAG3、SH2B3、SIT1;人力资源:2.2 - -4.5;p < 0.05)，血清抗炎效应物(IL-10、HSD11B1; HR: 0.2–0.3; p<0.05) and cellular junction proteins (CDSN, CNTNAP2, CXADR, ITGA11; HR: 0.4; p<0.05). The risk of short-term clinical relapse was specifically associated with a high serum level of pro-inflammatory effectors (IL-6, IL12RB1; HR: 3.5–3.6; p<0.05) and a low or high serum level of proteins mainly expressed in antigen presenting cells (CLEC4A, CLEC4C, CLEC7A, LAMP3; HR: 0.4–4.1; p<0.05).Conclusion We identified distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with CD stopping infliximab. These findings constitute an advance for the development of non-invasive biomarkers guiding the decision of anti-TNFα withdrawal.Data are available upon reasonable request. Data supporting the reported results (deidentified individual participant data and raw data of the PEA) can be shared upon request to the corresponding author. All the processed data are available in the supplemental tables. ER -